USANA HEALTH SCIENCES INC - 8-K Filing
USANA Health Sciences reports Q3 2026 net loss of $5.6 million and updates FY2026 guidance downward for sales and Adjusted EBITDA. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD DisclosureThe information disclosed above under Item 2, 9.01 below are incorporated herein by reference)